- 2021
-
Press releases - 01.02.2021
COVID-19 Vaccine Trials: Janssen’s Vaccine Candidate to be Tested by Covireivac
The Phase 3 clinical trial of a COVID-19 vaccine is to be launched via Covireivac, a platform set up under the auspices of Inserm and the university hospitals to centralize COVID-19 vaccine trials in France. Janssen, the pharmaceutical division of the Johnson & Johnson group, has obtained the authorizations[1] needed for ENSEMBLE 2, a trial evaluating the efficacy and safety of vaccine candidate Ad26.COV2.S in the prevention of COVID-19 in adults. In France, 1175 volunteers out of those registered on Covireivac will enroll in this clinical trial that will be conducted in 30,000 people across the world.
-
Press releases - 29.01.2021
Better Access to Education Reduces Differences in Cognitive Capacity Between Men and Women
Elderly women are currently at a higher risk than men of developing dementia, particularly Alzheimer’s disease. A phenomenon that could partially be explained by inequalities in access to education between the sexes during the first half of the 20th century. Researchers from Inserm and Université de Paris, in collaboration with University College London, have shown that certain cognitive capacities have improved in women over recent generations, and that this is linked to a larger number of women accessing higher education.
-
Press releases - 28.01.2021
Covid-19: Understanding Early Immune Response
As the COVID-19 pandemic continues, scientists are making significant headway in understanding the transmission of the SARS-CoV-2 coronavirus and the immune response it triggers at the time of infection. Researchers have provided new data on the very early stages of immune response.
-
Press releases - 27.01.2021
Discovery stops testing Remdesivir against Covid-19 for lack of evidence of its efficacy
The Discovery trial was originally launched in March 2020 by Inserm to evaluate possible treatments for Covid-19. On January 13th, 2021, the Discovery Europe trial Data Safety Monitoring Boards (DSMB) evaluated an interim report based on 776 patients of whom 389 received remdesivir and 387 received standard of care. The efficacy of the treatment was evaluated after 15 days and measured on the WHO-7-point ordinal scale. As a result of the evaluation, the DSMB recommended that patient recruitment be suspended.
-
Press releases - 25.01.2021
À l’Inserm, la lutte contre la pandémie de Covid-19 se poursuit
Pour faire face à la pandémie de Covid-19, mieux comprendre le virus et accompagner la prise en charge des maladies, les scientifiques de l’Inserm sont plus que jamais mobilisés.
-
Press releases - 13.01.2021
The “Cocktail Effect” of Endocrine Disruptors Better Understood
Endocrine disruptors can potentially become more harmful if mixed. Following on from research published in 2015, scientists continue to decipher the molecular mechanisms behind this phenomenon known as the “cocktail effect”.
-
Press releases - 04.01.2021
A New Mechanism Involved in the Development of Persistent Bacterial Infections
So-called “persistent” bacterial infections constitute a major public health problem and are linked to significant failures of antibiotic treatments. Researchers from Inserm and Université de Rennes 1, in collaboration with a team based in Switzerland, have identified a new mechanism to explain the persistence of Staphylococcus aureus.
- 2020
-
Press releases - 18.12.2020
COVID-19 Causes 3 Times More Deaths Than Seasonal Flu
A study by Inserm and Dijon University Hospital based on French nationwide data on around 130,000 patients hospitalized for either COVID-19 or seasonal influenza shows that the mortality rate among those admitted for COVID is three times higher than that of seasonal influenza.
-
Press releases - 09.12.2020
Discovery of a Mechanism Explaining the Beneficial Action of Cancer Drug Tamoxifen on the Cardiovascular System
A commonly used treatment in some forms of breast cancer, tamoxifen acts on the cancer cells by blocking the estrogen receptor (ER)a and thereby inhibiting their proliferation. However, the action of this drug appears to be more complex than that, with the addition of protective effects on the arteries that could reduce the risk of developing cardiovascular disease.
-
Press releases - 08.12.2020
Study – Particularly active antibodies to act as a barrier to SARS-CoV-2
Teams from the Pitié-Salpêtrière AP-HP hospital, Sorbonne University, Inserm and the Pasteur Institute have carried out work to study the role that IgA-type antibodies play in the protection of body against Covid-19 in the mucous membranes, in particular respiratory.